Xcout Intel
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. is a biotechnology company headquartered in Newton, Massachusetts. The company focuses on targeting cell states to deliver next-generation targeted cancer therapies.
Subscribe to see Auron Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Auron Therapeutics, Inc. at a glance
Auron Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $98.5M across the 5 funding rounds on record. Its most recent funding round raised $7.1M in August 2026. Xcout tracks 26 named people at Auron Therapeutics, Inc., including Katharine Yen (President).
Auron Therapeutics, Inc. leadership
- Katharine YenPresident
- Glenn GoddardChief Financial Officer
- Thomas Graeber, Ph.D.Chief Data Officer
- Katharine Yen, Ph.D.Founder & CEO
- Eytan Stein, M.D.Founder
- Matthew Vander Heiden, M.D., Ph.D.Founder
20 more named people on record for Auron Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Auron Therapeutics, Inc. funding rounds
At least $98.5M raised across the 5 rounds on record. The 3 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $7.1M | — | |
| Series B | $27.3M | 9 named | |
| Series B | $48M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Auron Therapeutics, Inc. competitors
A few of Auron Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Abcuro, Inc. is a biotechnology company headquartered in Newton, Massachusetts, focused on developing advanced immunotherapies to treat autoimmune diseases and cancer.
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Aurora Therapeutics is a biotechnology research company headquartered in Cambridge, Massachusetts. The firm focuses on advanced biomedical research and therapeutic development within the life sciences sector.
Orum Therapeutics is a biotechnology research company specializing in the development of targeted protein degraders for precision oncology using its TPD² approach. The company is headquartered in Daejeon, South Korea, with additional offices in Boston, Massachusetts.
Get Auron Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Auron Therapeutics, Inc. in Xcout Intel
- 26 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access